However, findings from randomized-controlled clinical trials revealed significant adverse effects of the humanized monoclonal NGF-antibody (tanezumab), including joint damage and rapidly progressive osteoarthritis, resulting in imposition of clinical hold by the Food and Drug Administration on all NGF inhibitors [1]. This evidence concerns the gene NGF and osteoarthritis.